Finding ways to improve immunotherapy for lung cancer patients with STK11 mutations
Biomarker-Driven Strategies to Overcome Immunotherapy Resistance in STK11-Deficient NSCLC
This study is looking at how certain features of lung cancer in patients with STK11 mutations can influence how well they respond to immunotherapy, with the hope of finding better ways to help those who struggle with current treatments.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project ID | NIH-10887315 on NIH RePORTER |
What this research studies
This research investigates how specific tumor characteristics in lung cancer patients with STK11 mutations affect their response to immunotherapy. By studying the tumor microenvironment and identifying new biomarkers, the team aims to understand why some patients do not respond to current treatments. They will validate a novel biomarker called STK11-MLDD to predict which patients might benefit from immunotherapy. The research also explores the role of certain immune regulators in promoting resistance to treatment, with the goal of developing more effective strategies for these patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are lung cancer patients who have been diagnosed with STK11-deficient tumors.
Not a fit: Patients with lung cancer who do not have STK11 mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for lung cancer patients with STK11 mutations, enhancing their chances of responding to immunotherapy.
How similar studies have performed: Previous research has shown promise in using biomarkers to predict responses to immunotherapy, making this approach both relevant and potentially impactful.
Where this research is happening
Columbus, UNITED STATES
- Ohio State University — Columbus, United States (Active)
Researchers
- Principal investigator: Kaufman, Jacob Marcus — Ohio State University
- Study coordinator: Kaufman, Jacob Marcus
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.